Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - calcium polystyrene sulphonate - powder for oral/rectal suspension - 99.934 percent weight/weight - drugs for treatment of hyperkalemia and hyperphosphatemia; polystyrene sulfonate

Israel - English - Ministry of Health

sanofi israel ltd - polystyrene sulphonate sodium - powder for suspension - polystyrene sulphonate sodium 99.934 % - polystyrene sulfonate - polystyrene sulfonate - treatment of hyperkalemia.

Malta - English - Medicines Authority

fresenius medical care nephrologica deutschland gmbh d-61346 bad homburg, germany - calcium - powder for oral suspension - calcium 1.8 mmol/g - all other therapeutic products

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - calcium polystyrene sulfonate - powder for oral or rectal suspension - 999mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - calcium polystyrene sulfonate - powder for oral or rectal suspension - 999mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

stanningley pharma ltd - calcium polystyrene sulfonate - powder for oral or rectal suspension - 854mg/1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

waymade b.v. - sevelamer hydrochloride - film-coated tablet - 400 milligram(s) - drugs for treatment of hyperkalemia and hyperphosphatemia; sevelamer

Ireland - English - HPRA (Health Products Regulatory Authority)

waymade b.v. - sevelamer hydrochloride - film-coated tablet - 800 milligram(s) - drugs for treatment of hyperkalemia and hyperphosphatemia; sevelamer

European Union - English - EMA (European Medicines Agency)

akebia europe limited - ferric citrate coordination complex - hyperphosphatemia; renal dialysis - drugs for treatment of hyperkalaemia and hyperphosphataemia - fexeric is indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (ckd).

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - all other therapeutic products - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis.renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.